DETAILED NOTES ON SITUS JUDI MBL77

mutations specified the fact that, as spelled out underneath, CLL therapy is based over the presence or absence of those mutations. The current consensus is always that, other than clonal mutations, subclonal mutations using a variant allelic frequency starting from 5 to 10% (and therefore beneath the edge of detection by regular molecular techniqu